$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths in 20081. Of all cancers, breast cancer is the most common with an incidence of over 13.8 million worldwide, and this incidence is increasing1. However, improvements in the diagnosis and treatment of breast cancer mean that the number of women surviving their breast cancer is also increasing, and is estimated to treble to 1.7 million by 2040 in the UK alone2. Breast radiotherapy forms an important part of many women’s breast cancer treatment, halving their risk of breast cancer recurrence and reducing the risk of breast cancer death by 3.8%3. With improvements in breast cancer survivorship, any long term side effects caused by breast cancer treatments are increasingly important. An innocent bystander in breast radiotherapy is the heart, which is exposed to unwanted radiation as a result of its proximity to radiation fields, especially during left breast irradiation. It is this unwanted dose to the heart that accounts for the 1% increase in non-breast cancer deaths associated with breast radiotherapy4. Recent evidence suggests that there is no threshold dose below which the late cardiac effects of breast radiotherapy do not occur5, making it critical for the oncology community to establish techniques which minimize cardiac doses without compromising breast tissue coverage. However, since breast radiotherapy accounts for approximately 30% of all radiotherapy treatments6, any new technique must be simple and inexpensive in order to be sustainable and avoid an unacceptable burden on healthcare resources.
There are a number of techniques which may be employed to reduce heart doses during breast radiotherapy. Multileaf collimation (MLC) is widely used in the UK [Royal College of Radiologists’ (UK) audit 2012] and although effective at sparing heart tissue, it risks simultaneously shielding breast tissue. Inverse planned intensity modulated radiotherapy (IMRT) improves target tissue conformality7, but may also increase low-dose irradiation of the heart, lungs and contralateral breast7,8. An increase in low dose irradiation of the heart is undesirable, particularly in light of the data from Darby et al5. In addition, inverse-planned IMRT is more resource-intensive, requiring greater physics and quality assurance (QA) time and expertise. Treating women in the prone (face-down) position may reduce cardiac doses in larger-breasted women9, however, questions remain over the positional reproducibility of this technique10. Breath-holding techniques, in which patients hold their breath during radiotherapy delivery, result in the heart being pushed down and away from the radiotherapy fields and may minimize the need for a compromise between target tissue coverage and organ-at-risk (OAR) sparing (Figure 1)11.
There are currently two main breath-holding techniques in clinical use. The first consists of a digital spirometer attached to a balloon valve. Patients breathe through a mouthpiece and a clip is placed on their nose to avoid nasal respiration. The spirometry trace is visualized on a monitor, and inspiration interrupted and held at a predetermined lung volume. The second method was primarily designed for use as a respiratory gating system, although it also has an built-in breath-hold setting. This system uses a video camera to record the motion of an infrared-reflecting marker placed on the chest of the patient. The vertical movement of the marker is displayed in real-time on a monitor, and treatment delivery commences once the marker moves into a pre-specified threshold zone. Both systems markedly reduce cardiac doses in patients receiving left breast radiotherapy. The spirometry-based technique significantly reduces the volume of myocardium irradiated12-14, as well as demonstrating comparable intra- and inter-fraction reproducibility compared to standard supine free-breathing breast radiotherapy15. Similarly, treatment using the infrared-reflecting markers reduces the mean dose to the heart by over 50%11,16,17, whilst maintaining target tissue coverage11. Such dosimetric savings are projected to equate to a 10 fold reduction in cardiac deaths18.
A drawback of these systems, however, and a barrier to widespread implementation, is their cost. Both systems require investment in the devices themselves, however, in the case of the spirometry system there are also ongoing costs as the mouthpieces are disposable, requiring a new mouthpiece for planning-CT as well as for each fraction of treatment. Cost, coupled with a lack of staff training, explains why only 4% of UK breast treatments were performed using breath-holding techniques in 2012 [Royal College of Radiologists’ (UK) audit]. Breath-holding techniques are in more widespread use in the rest of Europe, with 20% of centers using these techniques in 201019. One explanation for this is the development and implementation of a simple, inexpensive and equipment-free breath-holding technique, voluntary breath-hold (VBH). Until recently, however, data was lacking on the reproducibility of the VBH technique. A randomized study conducted at the Royal Marsden Hospital (Sutton, UK), The UK HeartSpare Study, has demonstrated that interfraction reproducibility with the VBH technique is comparable to that with the spirometry-based device. In addition, the VBH technique offers a time advantage at planning-CT and treatment setup and is preferred by patients and radiographers alike20. The VBH technique is currently being rolled out to ten UK radiotherapy centers to confirm that the technique is feasible in a multicenter setting and that heart-sparing is maintained (HeartSpare II). It is expected that this will pave the way for the UK-wide uptake of heart-sparing breast radiotherapy, and is likely to lead to a significant reduction in heart disease among UK breast cancer survivors.